Experience

Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Other orphan drugs and rare diseases

  • Presentation on the challenges and solutions of selecting and developing endpoints for use in paediatric populations and rare diseases
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)

Other nephrology experience

  • Payer objection handlers to support treatment in secondary hyperparathyroidism (SHPT)
  • Consultation on an FDA PRO claim in nephrology
  • COA strategies to complement a biology and renal/fibrotic portfolio
  • Qualitative literature and instrument review in atypical Haemolytic Uremic Syndrome (aHUS)

Other musculoskeletal experience

  • Economic analysis and trial design in hip replacement
  • Payer value slide deck in muscle relaxation management
  • Manuscript on a budget impact model for a biosimilar in rheumatology
  • General consultancy on economic and quality of life endpoints in planned trials in several musculoskeletal disease indications
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)
  • Review adherence questionnaire in a musculoskeletal disease

Other men’s health experience

  • Consultation for an FDA submission in andropause
  • Translation of a men’s health questionnaire
  • Patient perspective literature review for chronic pelvic pain in both men and women and premature ejaculation

Other HTA and reimbursement

  • All Wales Medicines Strategy Group – breakthrough cancer pain
  • All Wales Medicines Strategy Group – infertility
  • All Wales Medicines Strategy Group – iron overload
  • Joint Committee on Vaccination and Immunisation – HPV (UK)
  • Reimbursement authorities – heart failure (Belgium)
  • EU market access training workshop

Other gastrointestinal experience

  • Development of a global value dossier and budget impact model for capsule endoscopy for colonoscopy
  • Global value dossier for a therapy device in refractory ascites
  • Biosimilar payer communications in gastroenterology
  • Health economics support package in gastroenterology
  • Value proposition on a treatment for heartburn and indigestion
  • Cognitive debriefing and content validation of the diarrhoea symptom assessment measure
  • Cognitive debriefing of the Gastrointestinal Symptom Rating Scale Diarrhoea Domain in patients with Fabry’s disease
  • Support with interviews in paediatric vomiting
  • Managing patients with stoma: Adaptation of a Quality of Life Index (QLI) questionnaire to current needs for colostomy patients
  • Consultation and conduction of a discussion panel at the European Council of Enterostomal Therapy conference
  • Development of a manuscript based on modification of an ostomy study
  • Language validation interview for an ascites impact questionnaire
  • General consulting agreement in gastrointestinal assessments
  • Training work on post-operative nausea and vomiting
  • Strategic consultancy in gastrointestinal symptoms of Fabry’s disease
  • HEOR consulting services including clinical outcomes and regulatory approach

Other dermatology experience

  • Review article on adherence to topical therapies in dermatological conditions
  • HTA and reimbursement surveillance in dermatology
  • Biosimilar payer communications in dermatology
  • Literature and content searches for global value dossiers in dermatology
  • Psychometric evaluation of a PRO in hyperhidrosis
  • Development of a PRO and ClinRo for use in prurigo nodularis
  • Development and validation of a ClinRO to measure changes in peristomal skin
  • Global value dossier for a treatment for tissue management
  • Development and translation of a 6 item dermatology questionnaire into Danish
  • EMA dossier and literature review support in dermatology
  • Development and validation of the Skin Infection Rating Scale (SIRS)

Other CNS and neurological experience

  • Socio-economic analysis and phase I of a cost effectiveness analysis model for human cord graft
  • Global value dossier and e-v@luate instance in attention deficit hyperactivity disorder (ADHD)
  • Validation of the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
  • FDA consultancy and pre-NDA meeting in neurology
  • Literature review, conceptual models and mapping of generic utility instruments in neurology
  • Consultancy on an FDA submission for a central nervous system condition
  • Topline report on a side effect questionnaire in a central nervous system condition for submission

College voor zorgverzekeringen (CVZ – Netherlands)

  • Cost-effectiveness assessment for drug to be listed on the hospital ‘expensive drug list’
  • Cost-effectiveness assessment for an orphan drug
  • Diabetes (type 1)
  • Diaper dermatitis complicated by candidiasis in infants
  • Heart failure
  • Herpes zoster vaccine
  • HPV vaccine
  • Metabolic syndrome
  • Metastatic soft-tissue sarcoma

Scottish Medicines Consortium (SMC – UK)

  • Anthracycline extravasation
  • Breakthrough cancer pain
  • Breast cancer
  • Diabetes (type 2)
  • Epilepsy
  • Gastric cancer
  • Head and neck cancer
  • Hepatitis B
  • HIV
  • Homocystinuria
  • Infertility
  • Iron overload
  • Kidney failure
  • Lung cancer (non-small cell)
  • Parkinson’s disease
  • Psoriatic arthritis
  • Secondary hyperparathyroidism in end stage renal disease
  • Ulcerative colitis

Value dossiers

We have a vast amount of experience in this area including the creation of global/core value dossiers, AMCP dossiers, payer value/evidence dossiers and reimbursement dossiers.

  • Actinic keratosis
  • Anaesthesia
  • Ankylosing spondylitis
  • Aortic stenosis
  • Asthma
  • Atopic dermatitis
  • Attention deficit hyperactivity disorder (ADHD)
  • Breast cancer
  • Chronic obstructive pulmonary disease (COPD)
  • Colonoscopy
  • Crohn’s disease
  • Diabetes
  • Fabry disease
  • Febrile neutropenia
  • Fungal infections
  • Gastric cancer
  • Glaucoma
  • Glioblastoma
  • Heart failure
  • Heroin addiction
  • Hidradenitis suppurativa
  • Infertility
  • Inflammatory bowel disease
  • Influenza
  • Kidney disease/kidney failure
  • Leukaemia
  • Liver transplant
  • Lung cancer (small cell and non-small cell)
  • Melanoma
  • Multiple myeloma
  • Multiple sclerosis (MS)
  • Myelodysplastic syndrome
  • Myelofibrosis
  • Nutritional supplements
  • Osteoarthritis
  • Pain (acute pain, chronic pain and trauma pain)
  • Pancreatic cancer
  • Parkinson’s disease
  • Phenylketonuria
  • Prostate cancer
  • Psoriasis
  • Refractory ascites
  • Respiratory syncytial virus
  • Restless leg syndrome
  • Rheumatoid arthritis
  • Schizophrenia
  • Stress urinary incontinence
  • Surgery
  • Uveitis

Economic models

We have extensive experience in modelling across a wide range of indications – our model experience includes budget impact models, cost effectiveness models, scenario models, cost calculator models, value-based pricing models, cost offset models, and cost utility models. Our experience is vast in this area and models have been developed for a large number of countries and with adaptations for different markets. We have developed models and model adaptations throughout Europe (including the EU5, eastern Europe and Scandinavia), on a Global scale, and for the US, Canada, Japan, Australia, Mexico and Brazil.

  • Acromegaly
  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Allergies
  • Alzheimer’s disease
  • Anaemia
  • Anaesthesiology
  • Ankylosing spondylitis
  • Asthma
  • Benign prostatic hyperplasia
  • Bladder cancer
  • Breakthrough cancer pain
  • Breast cancer
  • Cardiometabolic risk
  • Chronic obstructive pulmonary disease (COPD)
  • Clostridium difficile infections
  • Colonoscopy
  • Colorectal cancer
  • Crohn’s disease
  • Diabetes (type 1 and 2)
  • Diabetic macular edema
  • Dyslipidaemia
  • Epilepsy
  • Esophogeal cancer
  • Gastric cancer
  • Head and neck cancer
  • Hepatitis C
  • HIV
  • Hormone replacement therapy
  • HPV
  • Human cord graft
  • Hypertension
  • Infection prevention
  • Infertility
  • Inflammatory bowel disease
  • Influenza
  • Leukaemia
  • Lung cancer (small cell and non-small cell)
  • Lymphomas
  • Melanoma
  • Mesothelioma
  • Multiple myeloma
  • Neuroendocrine tumours
  • Neuromuscular block
  • Osteoarthritis
  • Ovarian cancer
  • Pain
  • Parkinson’s disease
  • Phenylketonuria
  • Pneumococcal disease
  • Post-herpetic neuralgia
  • Psoriasis
  • Psoriatic arthritis
  • Renal cell carcinoma
  • Rheumatoid arthritis
  • Surgery and post-operative pain

Study endpoint reviews

  • Bone healing
  • Chronic pain in malignant cancer
  • Epilepsy
  • Fatigue and functioning in fibromyalgia
  • Female hypoactive sexual desire disorder
  • Fibromyalgia
  • Heart failure with preserved ejection fraction
  • Goitre
  • Inhaled insulin in type 2 diabetes
  • Opioid addiction
  • Rheumatoid arthritis
  • Review of a protocol and protocol amendment for a Phase II gastroparesis study which includes the CGSI as a primary endpoint

Regulatory briefing documents and PRO dossiers

  • Allergic rhinitis
  • Chronic obstructive pulmonary disease
  • Chronic pain
  • Constipation predominant irritable bowel syndrome
  • Crohn’s disease
  • End stage renal disease patients on haemodialysis
  • Epilepsy
  • Epoietin alfa in chronic kidney disease
  • Erythematous rosacea
  • Eyelash satisfaction questionnaire
  • Facial wrinkling
  • Functional digestive disorders (post-prandial distress syndrome)
  • Glioblastoma
  • Heart failure
  • Hereditary angioedema
  • Hereditary hemochromatosis
  • Hunter’s syndrome
  • Hypogonadism
  • Major depressive disorder
  • Multiple sclerosis
  • Pre-menstrual dysphoric disorder
  • Psoriasis
  • Retinal vein occlusion
  • Rheumatoid arthritis
  • Spinal cord injury
  • Smoking cessation
  • Ulcerative colitis

Endpoint reviews with an FDA component

  • Diabetic foot ulcers
  • Diabetic macular oedema
  • Diarrhoea-predominant irritable bowel syndrome
  • Dysmenorrhea
  • Epilepsy
  • Epoietin alfa in chronic kidney disease
  • Functional digestive disorders (post-prandial distress syndrome)
  • Hereditary angioedema
  • Hypogonadism
  • Major depressive disorder
  • Pain
  • Pulmonary arterial hypertension
  • Retinal vein occlusion
  • Rheumatoid arthritis

Qualitative interview methods

Addiction

  • Interviews and Rasch analysis in opioid addiction

Allergic conditions

  • Development of a COA strategy to measure treatment side effects for peanut allergy treatments

Autoimmune diseases

  • Assessing utility for flares in systemic lupus erythematosus in the UK, France, Spain, Australia and Canada, including training and managing local interviewing agencies and providing support to local teams
  • Key opinion leader contracting and additional interviews for assessing utility in various severities of flares in systemic lupus erythematosus

Cardiovascular disease

  • PRO claims for pulmonary arterial hypertension – endpoint review, regulatory support for the FDA and EMEA and qualitative patient interviews
  • Key opinion leader interviews on neurogenic orthostatic hypotension

Central nervous system/neurology

  • Development of an online therapy tool for depression along with a landscape analysis, structured and grey literature review, local language literature review, gap analysis, local language payer interviews and clinician interviews
  • Interview study to understand the experience of walking pain among patients with diabetic peripheral neuropathy
  • Interviews on the development of a composite trial endpoint for Dravet’s syndrome
  • Development of a conceptual framework and endpoint model in insomnia, plus qualitative patient interviews to confirm the validity of the conceptual framework and the psychometric validation of the final conceptual framework
  • Qualitative interviews in chronic migraine headaches
  • Regulatory consulting to support development of a structured diagnostic interview and severity scale in paediatric RLS, along with development of two manuscripts to document the development and validation process
  • Development and validation of a diagnostic interview and severity scale for paediatric RLS
  • Endpoint review and strategic recommendations on the application of the Zarit Burden Interview (ZBI) to assess caregiver burden in schizophrenia

Dermatology

  • Concept elicitation interviews in acne vulgaris to reach saturation
  • Analysis, reporting and patient interviews PRO in acne vulgaris
  • Patient interviews for the development of alopecia-related PRO measures
  • Qualitative interviews to evaluate the psychological impact of the brow satisfaction questionnaire and to validate in a post-chemotherapy population
  • Qualitative interviews to support the concept of psychological impact on the facial line outcomes questionnaire
  • Qualitative analysis of patient interviews to identify how subjects describe the severity of crow’s feet
  • Interviews with patient focus groups in psoriasis
  • Patient interviews and reporting on a photoguide in rosacea
  • Consulting on patient qualitative insight blogs with follow-up interviews to explore wound scar healing
  • Development of PRO and ClinRO instruments for alopecia totalis and alopecia universalis

Endocrinology and metabolic diseases

  • Patient interviews in type 2 diabetes for development of a new PRO measure
  • Interviews with patients with diabetes-induced edema in the USA
  • Interview study to understand the experience of walking pain among patients with diabetic peripheral neuropathy
  • Outcomes interviews in phenylketonuria, resource use and impact on patients
  • Development and validation of a patient-reported outcome measure for non-alcoholic steatohepatitis

Gastrointestinal diseases

  • In-depth interviews, instrument development and cognitive debriefing related to measurement of opioid-induced constipation
  • Patient interviews to assess content validity of an instrument for use in opioid-induced constipation
  • Qualitative interviews to develop a symptom measure in adult patients with eosinophilic esophagitis
  • Sub-group analysis of gastroparesis patients interviewed in exploratory phase, Rasch analysis and PCA on a 5 item scale
  • Patient interviews and qualitative work on IBS
  • Independent analysis, evidence saturation and report on 30 interviews in IBS-C
  • Long term safety study and participation interviews in chronic constipation and IBS-C
  • Manuscript based on the findings of the exit interview study of patients taking a treatment for IBS-C within a long term safety study
  • Interviews with clinicians to understand diagnoses of paediatric IBS-C and CC
  • Language validation interview for an ascites impact questionnaire
  • Support with interviews in paediatric vomiting

Genetic disorders

  • Qualitative interviews and development of a COA strategy for Down’s syndrome in adults and children
  • Patient interviews to support a PRO submission package in hereditary angioedema
  • Patient interviews for the face and content validation of the Patient Global Impression in hereditary angioedema
  • Endpoint review and caregiver interviews in Sanfilippo syndrome
  • Concept elicitation interviews in Barth Syndrome patients
  • Qualitative concept elicitation and case studies documenting the disease progression of Barth Syndrome

Haematology

  • Exit interviews to assess the impact of infusion frequency in haemophilia A
  • IRB submission for haemophilia patient interviews
  • Clinician and patient interviews for a PRO in iron overload
  • Caregiver interviews to support content validity of an ObsRO in a paediatric population with severe aplastic anaemia (SAA) and chronic immune thrombocytopenic purpura (CITP)
  • Qualitative interviews with patients with myelodysplastic syndrome

Immunology

  • Cognitive Debriefing of the Eosinophilic Esophagitis Activity Index (EEsAI)

Infectious diseases

  • Concept elicitation and cognitive debriefing interviews with hepatitis C patients in multiple countries
  • Consulting on the development of a PRO strategy for international HIV trials with interviews in the US and Puerto Rico

Men’s health

  • Patient interviews to support the development of an FDA dossier on an erection hardness score questionnaire

Musculoskeletal diseases

  • Patient interviews on rheumatoid arthritis
  • Pilot testing interviews on fibromyalgia fatigue
  • Patient interviews and manuscript on the development of a PRO strategy to support labelling claims in gout
  • Focus group interviews with patients with chronic low back pain
  • Qualitative exit interviews to assess the patient experience of treatment and clinical trial participation among patients with chronic low back pain and osteoarthritis

Nephrology

  • Qualitative interviews, conceptual model and strategic consulting on autosomal dominant polycystic kidney disease (ADPKD)

Oncology

  • Patient interviews to investigate side effects of breast cancer treatment
  • Qualitative interviews to assess equivalence of paper and electronically administered questionnaires in head and neck cancer
  • Qualitative interviews to understand the impact of non-small cell lung cancer (NSCLC) on quality of life
  • Qualitative interviews to understand the impact of NSCLC on caregivers and family members
  • Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
  • Patient interviews in lung cancer
  • Strategic PRO endpoint support, gap analysis and patient interviews in a biological therapy treatment for non-Hodgkin’s lymphoma
  • Pilot patient interviews in melanoma
  • Pre-screen interviews for the relative resource utilization of intravenous and subcutaneous drug administration in metastatic bone disease
  • Patient interviews in multiple myeloma and development of a poster on the results
  • Burden of relapse in multiple myeloma: communicating the findings from patient and physician interviews in the EU5
  • Expert interviews and amendment project to heath economic model for a treatment for breakthrough cancer pain

Ophthalmology

  • Patient interviews on glaucoma treatment characteristics and outcomes: unmet patient needs & value drivers
  • Brief literature reviews and patient interviews to inform development of PRO strategies in retinitis pigmentosa – stages 1, 2 and 3
  • Exploratory interviews to confirm the benefits of an experimental treatment in retinitis pigmentosis
  • Analysis and reporting on completed interviews about eyelid swelling

Respiratory diseases

  • Exit interviews and evaluation of the psychometric properties of the Asthma Daily Symptom Diary (ADSD) in severe asthma
  • Exit interviews to provide additional evidence of content validity for a quantitative study in asthma
  • Clinical trial exit interviews to characterise patients’ experience and treatment benefit in patients with activated phosphoinositide 3-kinase delta syndrome (APDS)
  • Content validation of a COA strategy for respiratory syncytial virus (RSV) and influenza in the elderly or in those with respiratory compromise
  • Exit interviews with caregivers and clinicians in a prospective study to assess the Paediatric Respiratory Syncytial Virus (RSV) Electronic Severity and Outcome Rating System (PRESORS)
  • Exit interviews on a connected inhaler system for asthma

Women’s health

  • Patient interviews and analysis/report on the Female Sexual Desire Profile (FSDP) and Female Sexual Encounter Profile (FSEP)
  • Qualitative research to assess the content validity of the dysmenorrhea daily diary (DysDD) in patients with endometriosis

Medical Devices

Allergic conditions

  • Focus groups assessing patient experience with nasal spray in allergic rhinitis, analysis of results and development of a report on concept elicitation and cognitive debriefing
  • Validation of the preference module of the Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q)
  • Manuscript on the development of the EARNS-Q
  • Regulatory support for the EARNS-Q
  • Preference questionnaire on allergic rhinitis spray devices

Cardiovascular disease

  • Demonstrating the value of a transcatheter heart valve in aortic stenosis
  • Gap analysis of PRO measures to substantiate labelling claims in angina trials of a drug-eluting stent (DES)
  • Development and validation of patient and clinician tools for myocardial infarction imaging
  • Analysis and reporting of myocardial infarction imaging validation study data
  • Clinician and patient satisfaction in an observational study in myocardial infarction SPECT imaging
  • Validation of clinician and patient questionnaires for myocardial infarction imaging
  • Demonstrating the value of a transcatheter heart valve in aortic stenosis
  • General consulting on a new stent device
  • Report on the cost of diagnosing vascular diseases with an MRA as the primary imaging modality

Central nervous system/neurology

  • Advisory board for a clinical screening tool for overactive bladder in multiple sclerosis (MS)
  • Development and validation of a clinical screening tool for overactive bladder in MS
  • Validation of a brief series of questions with a subgroup of MS patients

Dermatology

  • Testing PRO measures in electronic devices for rosacea

Endocrinology and metabolic diseases

  • Development of a manuscript on patient perceptions of prefilled insulin delivery devices
  • Consultation on a market research study on patient perceptions of pre-filled insulin pens
  • Injection Pen Assessment Questionnaire (IPAQ) field study in growth hormone deficiency
  • Establishing support of content validity for the modified Injection Pen Assessment Questionnaire (IPAQ) in growth hormone deficiency
  • Development of an instrument to assess subject perception of two gastric bands in obesity

Gastrointestinal diseases

  • Development of a global value dossier and budget impact model for capsule endoscopy for colonoscopy
  • Global value dossier for a therapy device in refractory ascites
  • Translation to support development of a value dossier and budget impact model in capsule endoscopy for colonoscopy
  • Patient Assessment of Constipation Symptoms (PAC-SYM) and analysis of a skin patch containing an opioid pain medication
  • Managing patients with stoma: Adaptation of a Quality of Life Index (QLI) questionnaire to current needs for colostomy patients

Haematology

  • Development and testing of a novel web-based tool to evaluate patient preference for a reconstitution device for haemophilia A in a real-world setting

Immunology

  • Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
  • Demonstrating the value of antibiotic resistance testing software
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)

Infectious diseases

  • Systematic literature review on the indirect protection from the HPV vaccination
  • Value demonstration and implementation plan for a new HPV test
  • Value pack for a HPV vaccine
  • Training sales reps on an interactive model for a HPV vaccine
  • Update of a budget impact model for a HPV vaccine
  • Cost-effectiveness analysis of a HPV vaccine for Spain
  • HTA submission for a HPV vaccine
  • Manuscripts on the German and Spanish cost-effectiveness analysis of a HPV vaccine
  • Analysis and reporting on the budget impact of a HPV vaccine
  • Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
  • Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
  • Update of a value dossier on an influenza vaccine
  • Cost-effectiveness analysis of an influenza vaccine
  • Review of influenza vaccine uptake data
  • Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
  • Communications package for an influenza vaccine
  • Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Communication of the economics of an influenza vaccine
  • Manuscripts on the health economics of a pneumococcal vaccine
  • Brief adaptation of a Markov model for a HPV vaccine
  • Adaptation of a Markov model on a HPV vaccine to Belgium
  • Development of a rationale for the need for a HPV vaccine
  • Communications package for an influenza vaccine
  • Adaptation of an influenza vaccine model to Belgium
  • Regulatory support for the validation of a questionnaire for influenza vaccination

Oncology

  • Cognitive debriefing interviews to assess usability of an ePRO device for use in forthcoming clinical trials in ovarian cancer

Ophthalmology

  • Formal recommendations on a regulatory briefing document for intraocular cataract lenses
  • Development of a PRO questionnaire to assess implantation of an intraocular lens in cataract patients
  • Cognitive interviews for the development of a PRO to assess intraocular lenses in cataract patients
  • Scientific dissemination of the patient-reported intraocular lens questionnaire
  • Etiology and meta-analysis of posterior cacular opacification comparing two lens types
  • Support on the intraocular cataract lenses (IOL) Expert Focus Group
  • Manuscript on HRQoL trial results of a new lens

Respiratory system

  • Global value dossier update and e-v@luate upload for an asthma device
  • Value proposition for a new metered dose inhaler to treat chronic obstructive pulmonary disease (COPD)
  • Structured literature review and qualitative interviews with payers/HCPs on a device for COPD
  • Development of a mini global value dossier for an asthma device
  • Structured literature reviews for paediatric wheeze detection
  • Rapid structured literature review of nebulisation inhalation efficiency in paediatric asthma and other respiratory conditions
  • Validation of the preference module of the Experience with Allergic Rhinitis Nasal Spray Questionnaire (EARNS-Q)
  • Manuscript on the development of the EARNS-Q
  • Focus groups assessing patient experience with nasal spray in allergic rhinitis, analysis of results and development of a report on concept elicitation and cognitive debriefing
  • Regulatory support for the EARNS-Q
  • Preference questionnaire on allergic rhinitis spray devices
  • Update to the pilot inference model for an inhaler used in the treatment of asthma
  • PRO strategy support for an inhaler treatment for COPD
  • Exit interviews on a connected inhaler system for asthma

Surgery and wound care

  • Training in a manual compression device for surgery
  • Strategic review of European market access potential for a surgical device
  • Value demonstration on a new wound care technology and the cost of pain management, allowing data to be tailored for local markets and local payers
  • AMCP dossiers for several surgical products
  • Identification of data inputs for a Canadian budget impact model in surgery

Urology and urogenital diseases

  • Systematic review of lithotripters for ureterolithiasis

Women’s health

  • Manuscript publication on a monthly contraceptive device
  • Modification, development and validation of an existing tool in order to explore satisfaction and tolerability for an intrauterine device (IUD) versus oral contraceptives
  • Modification of the EVAPIL-R in order to explore tolerability for an intrauterine system (IUS) versus an implantable contraceptive

Other

  • Value strategy training on access to medical devices
  • Panel and presentation on PRO research on medical devices

Polio

  • Burden of disease literature review on polio in the UK and Ireland